Testing PET/MRI monitoring for HER2-positive breast cancer before surgery
Part of Cancer clinical trials.
This early-phase study looks at how well PET/MRI scans can monitor treatment response in people with HER2-positive breast cancer before surgery. You may be asked to undergo specific scans during “neoadjuvant” therapy (treatment given before the main operation).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old
- Your breast cancer is HER2-positive from a tumor test (IHC 3+ or ISH positive); only one positive test is needed
- Your cancer is stage II–III and you have not started neoadjuvant treatment yet
- You have at least one measurable tumor spot on imaging that is bigger than 1 cm
- You can likely stay still on the scan table for about 1 hour and can have MRI safely
- You can have the specific MRI contrast (ProHance/gadoteridol) and are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study uses advanced PET/MRI scans to monitor how immunotherapy treatment works in people with triple-negative breast cancer that is PD-L1 positive. It may help doctors better track tumor changes in the body over time.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This study uses special scans (PET and MRI) to look at brain tumors in more detail. It aims to understand tumor metabolism and oxygen levels, which may help guide treatment.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This trial uses a special PET/MRI scan combined with artificial intelligence to see if it can predict whether HER2-positive breast cancer will completely disappear after treatment given before surgery. The goal is to learn who might avoid surgery or get a more tailored approach.
This study uses special PET/MRI scans to see how well breast cancer treatments are working. It aims to find better ways to monitor your cancer and guide your care.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.